SCHEMBL11301865

SCHEMBL11301865

C/N=C(\N)NC1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.61
EPHX1 P07099 6/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 1/20 0.44
EPHX2 P34913 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 2/20 0.43
LMNA P02545 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28300346 1.00 SIGMAR1 (0.61) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
Iodide SCHEMBL27688321 0.98 SIGMAR1 (0.59) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL9060289 0.98 SIGMAR1 (0.58) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL20111343 0.93
SCHEMBL26085538 0.78 SIGMAR1 (0.38) SIGMAR1ALDH1A1MAPTKDM4EMAPK1
SCHEMBL11297848 0.77 SIGMAR1 (0.61) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL2740862 0.76 SIGMAR1 (1.00) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL3319896 0.76 SIGMAR1 (1.00) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL3319901 0.76 SIGMAR1 (1.00) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1
SCHEMBL26456614 0.76 SIGMAR1 (1.00) SIGMAR1EPHX1ALDH1A1CYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 SIGMAR1 4227/4885EPHX1 2920/4885ALDH1A1 4728/4885
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 SIGMAR1 4227/4885EPHX1 2920/4885ALDH1A1 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.